Recent advances in natriuretic peptides in congestive heart failure

Bibliography

• McDONAGH TA, MORRISON CE, LAWRENCE A et al.: Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet (1997) 350(9081):829–833.
   PubMed Web of Science ®Google Scholar
• HOBBS RE, MILLS RIVI, YOUNG JB: An update on nesiritide for treatment of decompensated heart failure. Expert Opin. Investig. Drugs (2001) 10(5):935–942.
   PubMed Web of Science ®Google Scholar
• CHEN HH, BURNETT JC: The natriuretic peptides in heart failure: diagnostic and therapeutic potentials. Proc. Assoc. Am. Physicians (1999) 111(5):406–416.
   PubMedGoogle Scholar
• YAMAMOTO K, BURNETT JC Jr, REDFIELD MM: Effect of endogenous natriuretic peptide system on ventricular and coronary function in failing heart. Am. .1 Physiol (1997) 273(5 Pt. 2):H2406–H2414.
   Google Scholar
• RODEN R, ASANO K, WICHMANN S et al.: Inotropic effect of human B-type natriuretic peptide in the failing human heart. Card. Fail. (1998) 4:19.
   Google Scholar
• TAMURA N, OGAWA Y, CHUSHO H et al.: Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc. Natl Acad. Sci. USA (2000) 97(8):4239–4244.
   PubMed Web of Science ®Google Scholar
• STEVENS TL, BURNETT JC Jr, KINOSHITA M, MATSUDA Y, REDFIELD MM: A functional role for endogenous atrial natriuretic peptide in a canine model of early left ventricular dysfunction. I Clin. Invest. (1995) 95(3):1101–1108.
   PubMed Web of Science ®Google Scholar
• JEDLITSCHKY G, BURCHELL B, KEPPLER D: The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. Biol. Chem. (2000) 275(39):30069–30074.
   Web of Science ®Google Scholar
• RODEHEFFER RJ, NARUSE M, ATKINSON JB et al.: Molecular forms of atrial natriuretic factor in normal and failing human myocardium. Circulation (1993) 88(2):364–371. Expert Op/n. Investig. Drugs (2004) 13(6)649
   Google Scholar
• NAKAGAWA 0, OGAWA Y, ITOH H et al.: Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload. J. Clin. Invest. (1995) 96(3):1280–1287.
   Google Scholar
• PROTTER AA, WALLACE AM, FERRARIS VA, WEISHAAR RE: Relaxant effect of human brain natriuretic peptide on human artery and vein tissue. Jim. Hypertens. (1996) 9(5):432–436.
   Web of Science ®Google Scholar
• COLUCCI WS, ELKAYAM U, HORTON DP et al: Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl. J. Med. (2000) 343(4):246–253.
   PubMed Web of Science ®Google Scholar
• ••Large clinical trial evaluating the effect ofnesiritide in patients with decompensated heart failure. Haemodynarnic function and clinical status were assessed. The efficacy trial compared nesiritide with placebo (double-blind), the comparative trial compared nesiritide to standard agents (open-label). Co-medication allowed.
   Google Scholar
• BRUNNER-LA ROCCA HP, KAYE DM, WOODS RL, HASTINGS J, ESLER MD: Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J. Am. Coll Cardiol (2001) 37(5):1221–1227.
   PubMed Web of Science ®Google Scholar
• ABRAHAM WT, LOWES BD, FERGUSON DA et al.: Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure.' Card. Fail. (1998) 4(1):37–44.
   Google Scholar
• •Small placebo-controlled clinical trial evaluating the haemodynarnic and renal actions of BNP in patients with decompensated heart failure. No co-medication.
   Google Scholar
• YASUE H, YOSHIMURA M: Natriuretic peptides in the treatment of heart failure. Card. Fail. (1996) 2\(Suppl. 4):5277–5285.
   Google Scholar
• ARONSON D, BURGER AJ: Intravenous nesiritide (human B-type natriuretic peptide) reduces plasma endothelin-1 levels in patients with decompensated congestive heart failure. Am. Cardiol (2002) 90(4):435–438.
   PubMed Web of Science ®Google Scholar
• MICHAELS AD, KLEIN A, MADDEN JA, CHATTERJEE K: Effects of intravenous nesiritide on human coronary vasomotor regulation and myocardial oxygen uptake. Circulation (2003) 107(21):2697–2701.
   PubMed Web of Science ®Google Scholar
• YOSHIMURA M, YASUE H, MORITA E et al.: Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation (1991) 84(4):1581–1588.
   PubMed Web of Science ®Google Scholar
• YOSHIMURA M, YASUE H, OGAWA H: Pathophysiological significance and clinical application of ANP and BNP in patients with heart failure. Can. I Physic] Pharmacol (2001) 79(8):730–735.
   PubMed Web of Science ®Google Scholar
• JENSEN KT, CARSTENS J, PEDERSEN EB: Effect of BNP on renal hemodynamics, tubular function and vasoactive hormones in humans. Am. J. Physic] (1998) 274(1 Pt. 2):F63–F72.
   Google Scholar
• PUBLICATION COMMITTEE FOR THE VMAC INVESTIGATORS (VASODILATION IN THE MANAGEMENT OF ACUTE HEART CHF): Intravenous nesiritide versus nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. I. Jim. Med. A. (2002) 287(12):1531–1540.
   PubMed Web of Science ®Google Scholar
• ••Large clinical trial comparing nesiritidewith nitroglycerin and placebo. Primary outcome variables were PCWP and dyspnoea. Co-medication allowed.
   Google Scholar
• BURGER AJ, HORTON DP, LEJEMTEL T et al.: Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am. Heart J. (2002) 144(6):1102–1108.
   PubMed Web of Science ®Google Scholar
• BOERRIGTER G, COSTELLO-BOERRIGTER LC, CATALIOTTI A et al.: Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure. Circulation (2003) 107(5):686–689.
   PubMed Web of Science ®Google Scholar
• •First study to report the beneficial cardiorenal actions of the novel new pharmacological class of direct, NO-independent sGC stimulators in experimental heart failure.
   Google Scholar
• HILLEGE HL, GIRBES AR, DE KAM PJ et al.: Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation (2000) 102(2):203–210.
   Google Scholar
• DRIES DL, EXNER DV, DOMANSKI MJ, GREENBERG B, STEVENSON LW: The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J. Am. Coll. Cardiol (2000) 35(3):681–689.
   PubMed Web of Science ®Google Scholar
• KRUMHOLZ HM, CHEN YT, VACCARINO V et al.: Correlates and impact on outcomes of worsening renal function in patients 65 years of age with heart failure. Am. Cardiol (2000) 85 (9) :11104113.
   Web of Science ®Google Scholar
• SCHRIER RW, ABRAHAM WT: Hormones and hemodynamics in heart failure. N Engl. I Med. (1999) 341(8):577–585.
   PubMed Web of Science ®Google Scholar
• VAN DER ZK, HOUBEN AJ, HOFSTRA L, KROON AA, DE LEEUW PW: Hemodynamic and renal effects of low-dose brain natriuretic peptide infusion in humans: a randomized, placebo-controlled crossover study. Am. j Physic] Heart Circ. Physiol (2003) 285(3):H1206–H1212.
   PubMed Web of Science ®Google Scholar
• MARCUS LS, HART D, PACKER M et al.: Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation (1996) 94(12):3184–3189.
   Google Scholar
• •Small clinical trial assessing the haemodynarnic and renal actions of BNP in patients with CHE No co-medication.
   Google Scholar
• AKABANE S, MATSUSHIMA Y, MATSUO H et al.: Effects of brain natriuretic peptide on renin secretion in normal and hypertonic saline-infused kidney. Eur. j Pharmacol (1991) 198(2-3):143–148.
   PubMed Web of Science ®Google Scholar
• GOTTLIEB SS, BRATER DC, THOMAS I et al: BG9719 (CVT-124), an Al adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation (2002) 105(11):1348–1353.
   PubMed Web of Science ®Google Scholar
• CODY RJ, KUBO SH, PICKWORTH KK: Diuretic treatment for the sodium retention of congestive heart failure. Arch. Intern. Med. (1994) 154(17):1905–1914.
   PubMed Web of Science ®Google Scholar
• BAYLISS J, NORELL M, CANEPA-ANSON R, SUTTON G, POOLE-WILSON P: Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br. Heart j (1987) 57(1):17–22.
   PubMedGoogle Scholar
• CATALIOTTI A, BOERRIGTER G, COSTELLO-BOERRIGTER LC et al: Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Circulation (2004) 109:1680–1685.
   PubMed Web of Science ®Google Scholar
• KISHIMOTO I, HAMRA FK, GARBERS DL: Apparent B-type natriuretic peptide selectivity in the kidney due to differential processing. Can. Physiol. Pharmacol. (2001) 79(8):715–722.
   PubMed Web of Science ®Google Scholar
• ELLMERS LJ, KNOWLES JW, KIM HS et al.: Ventricular expression of natriuretic peptides in Nprl (-/-) mice with cardiac hypertrophy and fibrosis. Am. I Physiol. Heart Circ. Physiol. (2002) 283(2):H707–H714.
   PubMed Web of Science ®Google Scholar
• TSURUDA T, BOERRIGTER G, HUNTLEY BK et al.: Brain natriuretic Peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ. Res. (2002) 91(12):1127–1134.
   PubMed Web of Science ®Google Scholar
• KAPOUN AM, LIANG F, O'YOUNG G et al.: B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-031 in primary human cardiac fibroblasts. Fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ. Res. (2004)
   Google Scholar
• HAYASHI M, TSUTAMOTO T, WADA A et al.: Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. Am. Coll Cardiol. (2001) 37(7):1820–1826.
   PubMed Web of Science ®Google Scholar
• ••Clinical trial suggesting that ANP ascompared with nitroglycerin infusion has favourable effects on ventricular remodelling after myocardial infarction.
   Google Scholar
• KONSTAM MA, ROUSSEAU ME KRONENBERG MW et al.: Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. Circulation (1992) 86(2):431–438.
   Google Scholar
• KONSTAM MA, KRONENBERG MW, ROUSSEAU MF et al.: Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators. Circulation (1993) 88(5 Pt. 1):2277–2283.
   Google Scholar
• GROENNING BA, NILSSON JC, SONDERGAARD L et al.: Antiremodeling effects on the left ventricle during 13-blockade with metoprolol in the treatment of chronic heart failure. Am. Cardiol. (2000) 36(7):2072–2080.
   Web of Science ®Google Scholar
• DOUGHTY RN, WHALLEY GA, GAMBLE G, MacMAHON S, SHARPE N: Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. Am. Coll. Cardiol. (1997) 29(5):1060–1066.
   Google Scholar
• NORTHRIDGE DB, CURRIE PF, NEWBY DE et al.: Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure. Ear: J. Heart Fad. (1999) 1(1):67–72.
   PubMed Web of Science ®Google Scholar
• CLELAND JG, SWEDBERG K: Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. The International Ecadotril Multi-centre Dose-ranging Study Investigators. Lancet (1998) 351(9116):1657–1658.
   Google Scholar
• ROULEAU JL, PFEFFER MA, STEWART DJ et al.: Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet (2000) 356(9230):615–620.
   PubMed Web of Science ®Google Scholar
• CHEN HH, GRANTHAM JA, SCHIRGER JA et al.: Subcutaneous administration of brain natriuretic peptide in experimental heart failure. j. Am. Coll. Cardiol. (2000) 36(5):1706–1712.
   PubMed Web of Science ®Google Scholar
• •Study showing that chronic subcutaneous BNP administration has beneficial cardiorenal actions in experimental heart failure.
   Google Scholar
• CHEN HH, REDFIELD MM, SCHIRGER JA, CATALIOTTI A, BURNETT JC: Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure. Card. Fad. (2004) 10(2):115–119.
   PubMed Web of Science ®Google Scholar
• ••Small study investigating the effect ofchronic subcutaneous administration of BNP for 8 weeks. Angiotensin II decreased and left atrial volume and ventricular volumes tended to decrease. There was no indication for the development of tolerance with chronic administration.
   Google Scholar
• CHEN HH, LAINCHBURY JG, HARTY GJ, BURNETT JC, JR.: Maximizing the natriuretic peptide system in experimental heart failure: subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition. Circulation (2002) 105(8):999–1003.
   Google Scholar
• YANCY C, SALTZBERG M, BERKOWITZ R, HORTON D, SILVER M: Management of patients with chronic decompensated heart failure: results from the follow-up serial infusions of nesiritide (FUSION) trial. Circulation (2003) 108(17):IV–694:3156.
   Web of Science ®Google Scholar
• LISY 0, JOUGASAKI M, HEUBLEIN DM et al.: Renal actions of synthetic dendroaspis natriuretic peptide. Kidney Int. (1999) 56(2):502–508.
   Google Scholar
• LISY 0, LAINCHBURY JG, LESKINEN H, BURNETT JC Jr: Therapeutic actions of a new synthetic vasoactive and natriuretic peptide, dendroaspis natriuretic peptide, in experimental severe congestive heart failure. Hypertension (2001) 37(4):1089–1094.
   PubMed Web of Science ®Google Scholar
• CHEN HH, LAINCHBURY JG, BURNETT JC Jr: Natriuretic peptide receptors and neutral endopeptidase in mediating the renal actions of a new therapeutic synthetic natriuretic peptide dendroaspis natriuretic peptide. I Am. Coll Cardiol. (2002) 40(6):1186–1191.
   PubMed Web of Science ®Google Scholar
• FORSSMANN W, MEYER M, FORSSMANN K: The renal urodilatin system: clinical implications. Cardiovasc. Res. (2001) 51(3):450–462.
   PubMed Web of Science ®Google Scholar
• STASCH JP, BECKER EM, ALONSO-ALIJA C et al: NO-independent regulatory site on soluble guanylate cyclase. Nature (2001) 410(6825):212–215.
   PubMed Web of Science ®Google Scholar
• STASCH JP, SCHMIDT P, ALONSO-ALIJA C etal.: NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br. Pharmacol. (2002) 136(5):773–783.
   Google Scholar
• BOERRIGTER G, COSTELLO-BOERRIGTER LC, CATALIOTTI A etal.: Cardiorenal and humoral actions of the new heme-independent direct soluble guanylate cyclase activator BAY 58–2667 in experimental 651 Expert Op/n. Investig. Drugs (2004) 13(6) congestive heart failure. Circulation (2003) 108(17):IV-398:1840.
   Google Scholar
• HILLEMAN D, LENZ T, MALESKER M, FORAL P, HUNTER C: Pharmacoeconomic analysis of nesiritide in decompensated heart failure: a multi-center study. Circulation (2003) 108(17):IV–556:2535.
   Web of Science ®Google Scholar